ARTICLE
7 July 2026

Bipartisan Patients Before Monopolies Act Takes Aim At Pharmacies Owned By Health Insurers And PBMs

HB
Hall Benefits Law

Contributor

Strategically designed, legally compliant benefit plans are the cornerstone of long-term business stability and growth. As such, HBL provides comprehensive legal guidance on benefits in M&A, ESOPs, executive compensation, health and welfare benefits, retirement plans, and ERISA litigation matters. Responsive, relationship-driven counsel is the calling card of the Firm.
A bipartisan coalition reintroduced the Patients Before Monopolies Act in the 119th Congress after prior House and Senate versions introduced late in the 118th Congress were referred to the Judiciary Committees...
United States Ohio Consumer Protection
Hall Benefits Law’s articles from Hall Benefits Law are most popular:
  • with readers working within the Securities & Investment industries
Hall Benefits Law are most popular:
  • within Insurance topic(s)
  • with Senior Company Executives and HR

A bipartisan coalition reintroduced the Patients Before Monopolies Act in the 119th Congress after prior House and Senate versions introduced late in the 118th Congress were referred to the Judiciary Committees and did not advance. In the Senate, Sen. Elizabeth Warren, D-Mass., introduced S. 4509 for herself and Sens. Josh Hawley, R-Mo., John Fetterman, D-Pa., and Roger Marshall, R-Kan. In the House, Reps. Diana Harshbarger, R-Tenn., and Jake Auchincloss, D-Mass., are leading the companion effort, with original cosponsors including Reps. Jerry Nadler, D-N.Y., Greg Landsman, D-Ohio, Troy Nehls, R-Texas, and Buddy Carter, R-Ga.

The bill would force health insurance companies and pharmacy benefits managers (PBMs) to sell any pharmacies they own. According to Sen. Hawley, PBMs are driving up prescription drug costs and pushing out independent pharmacies. In response, a national PBM group claims that prescription drug manufacturers and wholesalers are driving up costs, not PBMs. That group characterizes the legislation as likely to weaken PBMs’ ability to negotiate with health insurance companies, employers’ self-insured health plans, and others, thereby increasing drug prices for Americans. Furthermore, the group warns that the bill could delay the delivery of specialty drugs to patients and reduce revenue, potentially costing some people their jobs. 

Sens. Warren and Hawley are also collaborating on the Break Up Big Medicine Act bill, which would ban various healthcare organizations from owning their buyers or vendors. 

The bill is currently under the jurisdiction of the Senate Judiciary Committee and the House Judiciary Committee. Ultimately, the bill’s sponsors forecast that the House Energy & Commerce Committee will likely share jurisdiction over the bill.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More